We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System
Product News

ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System

ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System
Product News

ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ProImmune Accelerates Development of Therapeutics with REVEAL™ B Cell Epitope Discovery System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ProImmune Ltd has launched the REVEAL™ B Cell Epitope Discovery System, a service designed to accelerate the development of biological therapies and understanding of diseases at a structural level.

The REVEAL™ service offers both comprehensive best consensus epitope prediction and rapid high throughput linear epitope mapping in vitro.

REVEAL™ consensus epitope prediction is a key tool in developing incisive hypotheses for downstream in vitro research. The service is based not only on primary sequence and 3D structure, but also incorporates any other additional information about the protein of interest from publicly available sources, and the experience and knowledge of ProImmune’s expert team to provide an intelligent consensus prediction to identify potential epitopes in a protein of interest.

Unlike hard to control assays that rely on recombinant or purified proteins, REVEAL™ linear epitope mapping relies on standardized peptide synthesis, which simplifies and accelerates the measurement of large numbers of samples.

Based on ProArray™ high-content peptide microarrays that can include thousands of peptides, the service provides a turnkey solution for applications such as vaccine subunit discovery, immunogenicity testing, and correlating antibody responses to protein targets with disease onset, progression and outcome.

Dr. Nikolai Schwabe, CEO of ProImmune, said: “The REVEAL™ B Cell Epitope Discovery System perfectly complements our long standing strength in T cell research and allows us to offer a complete solution to our customers for antigen discovery and antigenicity testing.”
Advertisement